<table id="table7" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7: Effect of Coadministered Drugs on the Pharmacokinetics of Atorvastatin</caption>
<col align="left" valign="top" width="25%"></col>
<col align="center" valign="middle" width="25%"></col>
<col align="center" valign="middle" width="25%"></col>
<col align="center" valign="middle" width="25%"></col>
<thead>
<tr>
<th align="center" stylecode="Botrule">Coadministered Drug and Dosing Regimen</th>
<th stylecode="Botrule"></th>
<th stylecode="Botrule">Atorvastatin</th>
<th stylecode="Botrule"></th>
</tr>
<tr>
<th></th>
<th>Dose (mg)</th>
<th>Change in AUC<footnote id="t7f1">Data given as x-fold change represent a simple ratio between coadministration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).</footnote>
</th>
<th>Change in C<sub>max</sub>
<footnoteref idref="t7f1"></footnoteref>
</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td>Cyclosporine 5.2 mg/kg/day, stable dose<footnote id="t7f2">
<content stylecode="italics">See <linkhtml href="#S5.1">Warnings and Precautions (5.1)</linkhtml>
</content> and <content stylecode="italics">
<linkhtml href="#S7">Drug Interactions (7)</linkhtml>
</content> for clinical significance.</footnote>
</td>
<td>10 mg QD for 28 days</td>
<td>↑8.7 fold</td>
<td>↑10.7 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>10 mg, SD</td>
<td>↑9.4 fold</td>
<td>↑8.6 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Telaprevir 750 mg q8h, 10 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>20 mg, SD</td>
<td>↑7.88 fold</td>
<td>↑10.6 fold</td>
</tr>
<tr stylecode="Botrule">
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr stylecode="Botrule">
<td>Saquinavir 400 mg BID/ritonavir 400 mg BID, 15 days<footnoteref idref="t7f2"></footnoteref>
<sup>,</sup>
<footnote>The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.</footnote>
</td>
<td>40 mg QD for 4 days</td>
<td>↑3.9 fold</td>
<td>↑4.3 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Clarithromycin 500 mg BID, 9 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>80 mg QD for 8 days</td>
<td>↑4.4 fold</td>
<td>↑5.4 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>10 mg QD for 4 days</td>
<td>↑3.4 fold</td>
<td>↑2.25 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Itraconazole 200 mg QD, 4 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>40 mg, SD</td>
<td>↑3.3 fold</td>
<td>↑20%</td>
</tr>
<tr stylecode="Botrule">
<td>Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>10 mg QD for 4 days</td>
<td>↑2.53 fold</td>
<td>↑2.84 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Fosamprenavir 1400 mg BID, 14 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>10 mg QD for 4 days</td>
<td>↑2.3 fold</td>
<td>↑4.04 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Nelfinavir 1250 mg BID, 14 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>10 mg QD for 28 days</td>
<td>↑74%</td>
<td>↑2.2 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Grapefruit Juice, 240 mL QD<footnoteref idref="t7f2"></footnoteref>
<sup>,</sup>
<footnote id="t7f3">Greater increases in AUC (up to 2.5 fold) and/or C<sub>max</sub> (up to 71%) have been reported with excessive grapefruit consumption (≥ 750 mL - 1.2 liters per day).</footnote>
</td>
<td>40 mg, SD</td>
<td>↑37%</td>
<td>↑16%</td>
</tr>
<tr stylecode="Botrule">
<td>Diltiazem 240 mg QD, 28 days</td>
<td>40 mg, SD</td>
<td>↑51%</td>
<td>No change</td>
</tr>
<tr stylecode="Botrule">
<td>Erythromycin 500 mg QID, 7 days</td>
<td>10 mg, SD</td>
<td>↑33%</td>
<td>↑38%</td>
</tr>
<tr stylecode="Botrule">
<td>Amlodipine 10 mg, single dose</td>
<td>80 mg, SD</td>
<td>↑15%</td>
<td>↓12%</td>
</tr>
<tr stylecode="Botrule">
<td>Cimetidine 300 mg QD, 4 weeks</td>
<td>10 mg QD for 2 weeks</td>
<td>↓Less than 1%</td>
<td>↓11%</td>
</tr>
<tr stylecode="Botrule">
<td>Colestipol 10 mg BID, 28 weeks</td>
<td>40 mg QD for 28 weeks</td>
<td>Not determined</td>
<td>↓26%<footnote>Single sample taken 8-16 h post-dose.</footnote>
</td>
</tr>
<tr stylecode="Botrule">
<td>Maalox TC® 30 mL QD, 17 days</td>
<td>10 mg QD for 15 days</td>
<td>↓33%</td>
<td>↓34%</td>
</tr>
<tr stylecode="Botrule">
<td>Efavirenz 600 mg QD, 14 days</td>
<td>10 mg for 3 days</td>
<td>↓41%</td>
<td>↓1%</td>
</tr>
<tr stylecode="Botrule">
<td>Rifampin 600 mg QD, 7 days (coadministered) <footnoteref idref="t7f2"></footnoteref>
<sup>,</sup>
<footnote id="t7f4">Due to the dual interaction mechanism of rifampin, simultaneous coadministration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.</footnote>
</td>
<td>40 mg, SD</td>
<td>↑30%</td>
<td>↑2.7 fold</td>
</tr>
<tr stylecode="Botrule">
<td>Rifampin 600 mg QD, 5 days (doses separated) <footnoteref idref="t7f2"></footnoteref>
<sup>,</sup>
<footnoteref idref="t7f4"></footnoteref>
</td>
<td>40 mg, SD</td>
<td>↓80%</td>
<td>↓40%</td>
</tr>
<tr stylecode="Botrule">
<td>Gemfibrozil 600 mg BID, 7 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>40 mg, SD</td>
<td>↑35%</td>
<td>↓Less than 1%</td>
</tr>
<tr stylecode="Botrule">
<td>Fenofibrate 160 mg QD, 7 days<footnoteref idref="t7f2"></footnoteref>
</td>
<td>40 mg, SD</td>
<td>↑3%</td>
<td>↑2%</td>
</tr>
<tr>
<td>Boceprevir 800 mg TID, 7 days</td>
<td>40 mg, SD</td>
<td>↑2.30 fold</td>
<td>↑2.66 fold</td>
</tr>
</tbody>
</table>